

Gross Paul Edward  
 Form 3  
 February 04, 2019

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Gross Paul Edward (Last) (First) (Middle)  C/O CLOVIS ONCOLOGY, INC., Â 5500 FLATIRON PARKWAY, SUITE 100 (Street)  BOULDER, Â CO Â 80301 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/01/2019	3. Issuer Name and Ticker or Trading Symbol Clovis Oncology, Inc. [CLVS]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) See Remarks	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	---	---	--	---

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,345	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

## Edgar Filing: Gross Paul Edward - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	Â (1)	01/25/2026	Common Stock	60,000	\$ 22.99	D	Â
Stock Option (right to buy)	Â (2)	03/27/2027	Common Stock	15,000	\$ 68.31	D	Â
Stock Option (right to buy)	Â (3)	03/01/2028	Common Stock	9,000	\$ 58.43	D	Â
Restricted Stock Units	Â (4)	03/27/2027	Common Stock	4,219	\$ (5)	D	Â
Restricted Stock Units	Â (6)	03/01/2028	Common Stock	9,000	\$ (5)	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gross Paul Edward C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301	Â	Â	Â See Remarks	Â

## Signatures

/s/ Paul Gross                      02/01/2019

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested as to 25% of the shares on January 25, 2017, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
- (2) The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
- (3) The option vests as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
- (4) The Restricted Stock Units vested as to 25% of the units on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
- (5) Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- (6) The Restricted Stock Units vest as to 25% of the units on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Â

### Remarks:

Executive Vice President, General Counsel and Chief Compliance Officer

## Edgar Filing: Gross Paul Edward - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.